|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue from contracts with customers | ||
| Cost of sales | ||
| Gross profit | ||
| Research and development costs | ||
| Selling and marketing expenses | ||
| Manufacturing and distribution costs | ||
| General and administration costs | ||
| Other gains/(losses)(net) | ||
| Operating profit | ||
| Finance income | ||
| Finance costs | ||
| (Loss)/profit before income tax | ||
| Income tax (expense)/benefit | ||
| (Loss)/profit for the year | ||
| (Loss)/profit for the year attributable to: | ||
| Owners of Telix Pharmaceuticals Limited | ||
| Other comprehensive (loss)/income: | ||
| Items that will not be reclassified to profit or loss in subsequent periods: | ||
| Changes in the fair value of investments at fair value through other comprehensive income | ||
| Items to be reclassified to profit or loss in subsequent periods: | ||
| Exchange differences on translation of foreign operations | ||
| Total comprehensive (loss)/income for the year | ||
| Total comprehensive (loss)/income for the year attributable to: | ||
| Owners of Telix Pharmaceuticals Limited | ||
| Earnings per share [abstract] | ||
| Basic (loss)/earnings per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share) | ||
| Diluted (loss)/earnings per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share) |
Loading...
